Gilead's chief executive calls lenacapavir a once in a decade medicine. The HIV treatment could push Gilead stock further up ...

The US drug administration has approved the use of the medication as an injection for use against the multidrug resistant ...

Lenacapavir has shown high efficacy in managing multidrug-resistant cases, offering hope to patients with limited alternatives. A significant breakthrough in treating the Human Immunodeficiency ...

A new drug is hugely effective at protecting people from HIV infection and needs to be injected only twice a year.

WHO is convening a Guideline Development Group (GDG) for the development of new guidelines on the use of injectable ...

A milestone was reached in the fight against HIV/AIDS with the development of Lenacapavir, a new injectable drug that ...

Addressing stigma, inequity, and access to HIV innovations remains critical to progress in the global HIV response, says IAS ...

Morgan Stanley has upgraded Gilead Sciences (GILD) to overweight from equal weight, citing the company's HIV drug lenacapavir. Read more here.

Hopkins said that lenacapavir was expected to be reviewed by the U.S. Food and Drug Administration in 2025, with the potential to dramatically reduce HIV infection. "This will be a critical next step ...

The general objective of this meeting is to develop WHO guidelines that will serve as a normative framework for the implementation of lenacapavir, a new HIV prevention product, and for simplified ...